-+ 0.00%
-+ 0.00%
-+ 0.00%

Simcere Receives China Clinical Trial Approval for SIM0725

PUBT·11/10/2026 12:09:51
Listen to the news
Simcere Receives China Clinical Trial Approval for SIM0725
  • Simcere Pharmaceutical received China’s National Medical Products Administration clearance for clinical trials of SIM0725, an anti-CD122 antibody for autoimmune diseases.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Simcere Pharmaceutical Group Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261110-12407421), on November 10, 2026, and is solely responsible for the information contained therein.